Proctitis: Infliximab

  IBD, Ulcerative Colitis

BOUGUEN, G., ROBLIN, X., BOURREILLE, A., FEIER, L., FILIPPI, J., NANCEY, S., … PEYRIN-BIROULET, L. (2010). Infliximab for refractory ulcerative proctitis. Alimentary Pharmacology & Therapeutics, 31(11), 1178–1185. doi:10.1111/j.1365-2036.2010.04293.x


Efficacy of infliximab in treating ulcerative proctitis remains unknown.


To evaluate the clinical, biological and endoscopic efficacy of infliximab therapy in refractory proctitis.


The charts of 420 patients treated with infliximab for ulcerative colitis were reviewed. Thirteen patients were treated with infliximab for refractory ulcerative proctitis in six referral centres between 2005 and 2009.


Following infliximab therapy induction, 9/13 patients (69%) had a complete response (defined as absence of diarrhoea and blood), 2/13 (15%) had a partial response and 2/13 (15%) were primary nonresponders. The median follow-up was 17 months (range, 3-48). Among the 11 patients with clinical response after infliximab induction therapy, 9 (82%) patients maintained response at last follow-up. Disappearance of rectal disorders was observed in all nine patients who maintained clinical response at last follow-up. Following infliximab induction therapy, the mean CRP level fell from 12.8 mg/L to 4.7 mg/L. Endoscopic evaluation was performed before and after infliximab in seven patients, showing an improvement in mucosal lesions in four patients, persistent mild endoscopic activity in two patients and no improvement in one patient. One patient underwent proctocolectomy.


Infliximab therapy seems to be effective in inducing and maintaining a clinical response in refractory ulcerative proctitis.